San Diego regenerative medicine company ViaCyte announced this week that the Food and Drug Administration (FDA) approved their Investigational New Drug (IND) Application for PEC-Direct, a cell-based therapy to treat patients at risk for severe complications caused by type 1 diabetes. In the US, IND approval is the final regulatory step required before a therapy … Continue reading ViaCyte Advances Cell Replacement Therapy for High Risk Type 1 Diabetes
California Institute for Regenerative Medicine
Texas tries to go it alone in offering unproven stem cell therapies to patients
One of the most hotly debated topics in stem cell research is whether patients should be able to have easier access to unproven therapies using their own stem cells, at their own risk, and their own cost. It’s a debate that is dividing patients and physicians, researchers and lawmakers. In California, a bill working its … Continue reading Texas tries to go it alone in offering unproven stem cell therapies to patients
Stem cell-derived blood-brain barrier gives more complete picture of Huntington’s disease
Like a sophisticated security fence, our bodies have evolved a barrier that protects the brain from potentially harmful substances in the blood but still allows the entry of essential molecules like blood sugar and oxygen. Just like in other parts of the body, the blood vessels and capillaries in the brain are lined with endothelial … Continue reading Stem cell-derived blood-brain barrier gives more complete picture of Huntington’s disease
UCSD scientists devise tiny sensors that detect forces at cellular level
A big focus of stem cell research is trying to figure how to make a stem cell specialize, or differentiate, into a desired cell type like muscle, liver or bone. When we write about these efforts in the Stem Cellar, it’s usually in terms of researchers identifying proteins that bind to a stem cell’s surface … Continue reading UCSD scientists devise tiny sensors that detect forces at cellular level
Positively good news from Asterias for CIRM-funded stem cell clinical trial for spinal cord injury
Whenever I give a talk on stem cells one of the questions I invariably get asked is “how do you know the cells are going where you want them to and doing what you want them to?” The answer is pretty simple: you look. That’s what Asterias Biotherapeutics did in their clinical trial to treat … Continue reading Positively good news from Asterias for CIRM-funded stem cell clinical trial for spinal cord injury
Stem cell stories that caught our eye: update on Capricor’s heart attack trial; lithium on the brain; and how stem cells do math
Today our partners Capricor Therapeutics announced that its stem cell therapy for patients who have experienced a large heart attack is unlikely to meet one of its key goals, namely reducing the scar size in the heart 12 months after treatment. The news came after analyzing results from patients at the halfway point of the … Continue reading Stem cell stories that caught our eye: update on Capricor’s heart attack trial; lithium on the brain; and how stem cells do math
A call to put the ‘public’ back in publication, and make stem cell research findings available to everyone
Thomas Gray probably wasn’t thinking about stem cell research when, in 1750 in his poem “Elegy in a Country Churchyard”, he wrote: “Full many a flower is born to blush unseen”. But a new study says that’s precisely what seems to happen to the findings of many stem cell clinical trials. They take place, but … Continue reading A call to put the ‘public’ back in publication, and make stem cell research findings available to everyone
jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
When the US Congress approved, and President Obama signed into law, the 21st Century Cures Act last year there was guarded optimism that this would help create a more efficient and streamlined, but no less safe, approval process for the most promising stem cell therapies. Even so many people took a wait and see approach, … Continue reading jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
CIRM’s Randy Mills leaving stem cell agency to take on new challenge
Some news releases are fun to write. Some less so. The one that CIRM posted today definitely falls into that latter group. It announced that CIRM’s President and CEO, Randy Mills, is leaving us to take up the role of President and CEO at the National Marrow Donor Program – NMPD/Be The Match. It’s a … Continue reading CIRM’s Randy Mills leaving stem cell agency to take on new challenge
Stem cell-derived, 3D brain tissue reveals autism insights
Studying human brain disorders is one of the most challenging fields in biomedical research. Besides the fact that the brain is incredibly complex, it’s just plain difficult to peer into it. For one thing, it’s not practical, let alone ethical, to drill into an affected person’s skull and collect brain cells to learn about their … Continue reading Stem cell-derived, 3D brain tissue reveals autism insights
The Stem Cellar 